Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B

Baik Hahm Ki Baik Hahm, Hyub Han Kwang Hyub Han, Ho Kim Won Ho Kim, Soon Yim Dae Soon Yim, Yoon Chon Chae Yoon Chon, Myung Moon Young Myung Moon, Kyung Kang Jin Kyung Kang, Suh Park In Suh Park, Koo Youn Jung Koo Youn, Evelyne Deschamps de Paillette

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


In order to assess whether polyadenylic. polyuridylic acid [poly(A).poly(U)] can be used as a new therapeutic agent for the treatment of chronic hepatitis B, 19 patients with histologically proven chronic active hepatitis B were injected intravenously with 100-150 mg of poly(A).poly(U) weekly for six weeks. Changes in alanine aminotransferase (ALT) levels, 2′.5′-olidoadenylate synthetase (2.5′.5′-AS) activities and HBV markers were sequentially checked during and after treatments. Serum ALT levels were decreased gradually and 2′.5′-AS activities were significantly increased after initiation of poly(A).poly(U) injections. At the end of this trial (24th week) we have observed the normalizations of elevated ALT levels in 14 (73.7%), negative conversion of HBeAg in 11 (57.9%) and loss of HBV-DNA in 12 out of 19 patients (63.1%). Complete responses which had both normalization of ALT levels and negative conversion of HBeAg were noted in 11 patients (57.9%) and partial responses showing either normalization of ALT levels or negative conversion of HBeAg alone were in four out of 19 patients (21.1%). No notable adverse effects were observed during the treatments and follow-up period. It can be concluded that poly(A).poly(U) seems to be effective in the treatment of chronic active hepatitis B and has an advantage of being free of significant side effects.

Original languageEnglish
Pages (from-to)217-225
Number of pages9
JournalInternational Journal of Immunopharmacology
Issue number3
Publication statusPublished - 1994 Mar

Bibliographical note

Funding Information:
Acknowledgements -- This work was supported, partly, by the grant from Institut Henri Beaufour, Paris 7b, France. The authors would like to thank Professor Hyun-Sook Kim, Department of Clinical Pathology, Yonsei University for giving help in measuring HBV-DNA and Mr Eun-Sung Kim, Institute of Cheil Foods & Chemical's Inc., Research & Development Center, Korea, for mearuring 2'.5'-AS activities.

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology


Dive into the research topics of 'Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B'. Together they form a unique fingerprint.

Cite this